Clearmind Medicine/$CMND
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Clearmind Medicine
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
- Ticker
- $CMND
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Vancouver, Canada
- Website
- www.clearmindmedicine.com
CMND Metrics
BasicAdvanced
$2.5M
-
-$118.41
0.46
-
Price and volume
Market cap
$2.5M
Beta
0.46
52-week high
$7.16
52-week low
$5.25
Financial strength
Current ratio
4.309
Quick ratio
4.282
Long term debt to equity
0.008
Total debt to equity
0.139
Interest coverage (TTM)
-1,196.98%
Profitability
EBITDA (TTM)
-8.856
Effective tax rate (TTM)
-0.17%
Management effectiveness
Return on assets (TTM)
-53.08%
Return on equity (TTM)
-106.98%
Valuation
Price to book
0.12
Price to tangible book (TTM)
0.12
Price to free cash flow (TTM)
-0.053
Free cash flow yield (TTM)
-1,879.70%
Free cash flow per share (TTM)
-111.65
Growth
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.